Interesting enobosarm Phase II study

[Sicsemptyran]

Let me start by saying I'm not suggesting this means people should use SARMs, but I am a fan of all research on anabolic agents, as it reduces the stigma and has the potential to incentivize research into drug classes that have been completely untouched by pharma for years.

In this study, participants were given very low doses of enobosarm/ostarine while taking a GLP-1, and showed 71% less lean mass loss while achieving an additional 27% fat loss.

This could be very interesting, because if approved this would be a non-controlled, oral anabolic agent that would potentially increase the amount of the general population using anabolics and also incentivize pharma to create newer, more effective anabolic agents. Top line data and announcement below.

https://ir.verupharma.com/news-events/press-releases/detail/225/veru-announces-positive-topline-data-from-phase-2b-quality

 

[BamaCrazy]

There seems to be a lot of studies that aim to assist weight loss while preventing muscle loss.

With $170M, BioAge Joins Lilly in Oral, Muscle Preserving Obesity Treatment

BioAge Labs has completed an oversubscribed $170 million Series D financing, the proceeds of which will support Phase II trials of a therapy combining the company's azelaprag with Eli Lilly's trzepatide.

www.genengnews.com

 

[Sicsemptyran]

There seems to be a lot of studies that aim to assist weight loss while preventing muscle loss.

With $170M, BioAge Joins Lilly in Oral, Muscle Preserving Obesity Treatment

BioAge Labs has completed an oversubscribed $170 million Series D financing, the proceeds of which will support Phase II trials of a therapy combining the company's azelaprag with Eli Lilly's trzepatide.

www.genengnews.com

That's an interesting one I'm surprised I missed. Looks like essentially an exercise mimetic, which would be great to see if we have one that actually works. Past famous ones (cardarine) have obviously not made it through trials.

 

[BamaCrazy]

That's an interesting one I'm surprised I missed. Looks like essentially an exercise mimetic, which would be great to see if we have one that actually works. Past famous ones (cardarine) have obviously not made it through trials.

When I saw the headline I was certain it was going to be SLU-PP + Tirzepetide. Which is also an exercise memetic.

 

[Corduroy]

With such a low dose (as low as 3mg daily) of enobosarm aka ostarine, might it be possible to get the benefits seen in the study without endogenous androgen suppression or the need to even cycle? Is anabolic microdosing a thing?

 

[AlexDavis43]

With such a low dose (as low as 3mg daily) of enobosarm aka ostarine, might it be possible to get the benefits seen in the study without endogenous androgen suppression or the need to even cycle? Is anabolic microdosing a thing?

Welcome to Meso. Check out the New Member Introduction thread.

 

[Corduroy]

Welcome to Meso. Check out the New Member Introduction thread.

Thanks! Done, and wrote my intro message. Sounds like anabolic microdosing = micro results when it comes to hypertrophy, but maybe it has a place for sparing lean mass during weight loss. I'm still wondering if enobosarm will require cycling at the 3mg or 6mg dose if the pharma company applies for FDA approval.

 

[Sicsemptyran]

With such a low dose (as low as 3mg daily) of enobosarm aka ostarine, might it be possible to get the benefits seen in the study without endogenous androgen suppression or the need to even cycle? Is anabolic microdosing a thing?

I think there’s a solid body of evidence that we in fact do not need large doses of anabolics to maintain tissue, and given that the target audience here is elderly on GLP’s, I imagine even a small dose of an anabolic agent likely makes a large difference.

Detailed safety data has yet to be released, but given that the study hasn’t been halted we can infer it’s not too bad. Unfortunately, SARMs in general have been shown to have a lot of the negative effects of oral AAS’s, and I have to imagine these small doses would just be that (but smaller).

 

[Corduroy]

RMs in general have been shown to have a lot of the negative effects of oral AAS’s, and I have to imagine these small doses would just be that (but smaller).

I did a brief PubMed search tonight and came across a couple of articles, one that showed enobosarm/ostarine toxicity to heart muscle cells (in vitro) and another that showed increased prostate hypertrophy (in rats). The clinical trials (aside from the GLP study) don't seem very impressive either, although it's interesting that it might actually have utility as adjunctive treatment for breast cancer.

Incretin agonist + myostatin inhibitor sounds like a much more promising approach for body recomp, or at least that's what the pharma companies seem to think.